Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 3, 1997, Pages 654-660

  Kempf, Dale J ^a   Marsh, Kennan C ^a   Kumar, Gondi ^a   Rodrigues, A David ^a   Denissen, Jon F ^a   McDonald, Edith ^a   Kukulka, Michael J ^a   Hsu, Ann ^a   Granneman, G Richard ^a   Baroldi, Paolo A ^a   Sun, Eugene ^a   Pizzuti, David ^a   Plattner, Jacob J ^a   Norbeck, Daniel W ^a   Leonard, John M ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; CYTOCHROME P450; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANIMAL EXPERIMENT; ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ELIMINATION; DRUG METABOLISM; DRUG MIXTURE; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER MICROSOME; MALE; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0031035968     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.3.654     Document Type: Article

References (34)

1. Cameron, B., M. Heath-Chiozzi, S. Kravci, R. Mills, A. Potthoff, D. Henry, The Advanced HIV Ritonavir Study Group, and J. Leonard. 1996. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir, abstr. LB6a. In Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections. Infectious Diseases Society of America for the Foundation of Retrovirology and Human Health, Alexandria, Va.
2. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
3. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. E. Squires, P. J. Deutsch, and E. A. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
4. Danner, S. A., A. Carr, J. M. Leonard, L. M. Lehman, F. Gudiol, J. Gonzales, A. Raventos, R. Rubio, E. Bouza, V. Pintado, A. Gil Aguado, J. Garcia de Lomas, R. Delgado, J. C. C. Borleffs, A. Hsu, J. Valdes, C. A. B. Boucher, and D. A. Cooper. 1995. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333: 1528-1533.
5. Dorsey, B. D., R. B. Levin, S. L. McDaniel, J. P. Vacca, J. P. Guare, P. L. Darke, J. A. Zugay, E. A. Emini, W. A. Schleif, J. C. Quintero, J. H. Lin, I.-W. Chen, M. K. Holloway, P. M. D. Fitzgerald, M. G. Axel, D. Ostovic, P. S. Anderson, and J. R. Huff. 1994. L-735.524: the design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 37:3443-3451.
6. Farrar, G., A. M. Mitchel, H. Hooper, F. Stewart, and S. L. Malcolm. 1994. Prediction of potential drug interactions of saquinavir (Ro 31-8959) from in vitro data. Br. J. Clin. Pharmacol. 38:162P.
7. Greenberg, R. N. 1984. Overview of patient compliance with medication dosing: a literature review. Clin. Ther. 4:592.
8. Gulick, R., J. Mellors, D. Havlir, J. Eron, C. Gonzalez, D. McMahon, D. Richman, F. Valentine, L. Jonas, A. Meibohm, R. Chiou, P. Deutsch, E. Emini, and J. Chodakewitz. 1996. Potent and sustained antiretroviral activity of indinavir in combination with zidovudine and lamivudine, abstr. LB7. In Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections. Infectious Diseases Society of America for the Foundation of Retrovirology and Human Health. Alexandria, Va.
9. Heath-Chiozzi, M., J. Leonard, D. Henry, R. Mills, A. Potthoff, The Advanced HIV Ritonavir Study Group, and B. Cameron. 1996. Anti HIV activity and lymphocyte surrogate marker response dynamics to ritonavir therapy in advanced HIV immunodeficiency, abstr. LB6b. In Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections. Infectious Diseases Society of America for the Foundation of Retrovirology and Human Health, Alexandria, Va.
10. Hensleigh, M., M. Chiba, and J. H. Lin. 1995. Hepatic and intestinal metabolism of MK-639. an HIV protease inhibitor, in rats and human. Pharm. Res. 12:S-374.
11. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
12. Jacobsen, H., M. Haenggi, M. Ott, I. B. Duncan, S. Vella, and J. Mous. 1995. In vivo resistance to HIV proteinase inhibitor saquinavir - an update. AIDS Res. Hum. Retroviruses 11:S169.
13. Kalish, V., S. Kaldor, B. Shetty, J. Tatlock, J. Davies, M. Hammond, B. Dressman, J. Fritz, K. Appelt, S. Reich, L. Musick, B. W. Wu, and K. Su. 1995. Iterative protein structure-based drug design and synthesis of HIV protease inhibitors. Eur. J. Med. Chem. 30:S201-S214.
14. Kempf, D., K. C. Marsh, J. F. Denissen, E. McDonald, S. Vasavanonda, C. A. Flentge, B. E. Green, L. Fino, C. H. Park, X.-P. Kong, N. E. Wideburg, A. Saldivar, L. Ruiz, W. M. Kati, H. L. Sham, T. Robins, K. D. Stewart, A. Hsu, J. J. Plattner, J. M. Leonard, and D. W. Norbeck. 1995. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92:2484-2488.
15. Kempf, D. J., K. C. Marsh, L. C. Fino, P. Bryant, A. Craig-Kennard, H. L. Sham, C. Zhao, S. Vasavanonda, W. E. Kohlbrenner, N. E. Wideburg, A. Saldivar, B. E. Green, T. Herrin, and D. W. Norbeck. 1994. Design of orally bioavailable, symmetry-based inhibitors of HIV protease. Bioorg. Med. Chem. 2:847-858.
16. 2-symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 35:2209-2214.
17. Keogh, A., P. Spratt, C. McCosker, P. Macdonald, J. Mundy, and A. Kaan. 1995. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N. Engl. J. Med. 333:628-633.
18. Kim, E. E., C. T. Baker, M. D. Dwyer, M. A. Murcko, B. G. Rao, R. D. Tung, and M. A. Navia. 1995. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. 117:1181-1182.
19. Kronbach, T., V. Fischer, and U. A. Meyer. 1988. Cyclosporine metabolism in human liver. Identification of a cytochrome P-450 III gene family as the major cyclosporine-metaholizing enzyme explains interactions of cyclosporine with other drugs. Clin. Pnarmacol. Ther. 43:630-635.
20. Kumar, G. N., A. D. Rodrigues, A. M. Buko, and J. F. Denissen. 1996. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 277:423-431.
21. Markowitz, M., M. Saag, W. G. Powderly, A. M. Hurley, A. Hsu, J. M. Valdes, D. Henry, F. Sattler, A. La Marca, J. M. Leonard, and D. D. Ho. 1995. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333:1534-1539.
22. Marsh, K. C. Unpublished data.
23. Molla, A., M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H.-M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. B. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
24. Nedelcheva, V., and I. Gut. 1994. P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica 24:1151-1175.
25. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 271:1582-1586.
26. 2 symmetry-based human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. 39:1559-1564.
27. Roberts, N. A., J. A. Martin, D. Kinchington, A. V. Broadhurst, J. C. Craig, I. B. Duncan, S. A. Galpin, B. K. Handa, J. Kay, A. Kröhn, R. W. Lambert, J. H. Merrett, J. S. Mills, K. E. B. Parkes, S. Redshaw, A. J. Ritchie, D. L. Taylor, G. J. Thomas, and P. J. Machin. 1990. Rational design of peptide-based HIV proteinase inhibitors. Science 248:358-361.
28. Rodrigues, A. D., D. F. V. Lewis, C. Ioannides, and D. V. Parke. 1987. Spectral and kinetic studies of the interaction of imidazole anti-fungal agents with microsomal cyiochromes P-45U. Xenobiotica 17:1315-1327.
29. Rodrigues, A. D., D. Mulford, R. Lee, B. Surber, M. Kukulka, M. S. Shet, and R. W. Estabrook. 1995. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P450 3A4 (CYP3A4) and NADPH-P450 reductase. Drug Metab. Dispos. 23:765-775.
30. Schapiro, J. M., M. A. Winters, F. Stewart, B. Efron, J. Norris, M. J. Kozal, and T. C. Merigan. 1996. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann. Intern. Med. 124:1039-1050.
31. Stein, D. S., D. G. Fish, J. A. Bilello, S. L. Preston, G. L. Martineau, and G. L. Drusano. 1996. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 10:485-492.
32. Vacca, J. P., B. D. Dorsey, W. A. Schlief, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, O. M. Blahy, E. Roth, V. V. Sardana, A. J. Schlabach, P. I. Graham, J. H. Condra, L. Gotlib, M. K. Holloway, J. Lin, I.-W. Chen, K. Vastag, D. Ostovic, P. S. Anderson, E. A. Emini, and J. R. Huff. 1994. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Nail. Acad. Sci. USA 91:4096-4100.
33. Vincent, S. H., B. V. Karanam, S. K. Painter, and S.-H. L. Chiu. 1992. In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. Arch. Biochem. Biophys. 294:454-460.
34. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.